Francesco Pepe

List of Publications by Citations

Source: https://exaly.com/author-pdf/3738093/francesco-pepe-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

722 15 24 g-index

73 1,043 3.7 4 L-index

ext. papers ext. citations

| # | Paper | IF | Citations |
|----|---|---------------|-----------|
| 66 | Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017 , 116, 802-810 | 8.7 | 93 |
| 65 | EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. <i>Cancer Cytopathology</i> , 2013 , 121, 552-60 | 3.9 | 58 |
| 64 | The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020 , 85, 101994 | 14.4 | 51 |
| 63 | Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2017 , 125, 615-626 | 3.9 | 43 |
| 62 | ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. <i>Cancer Cytopathology</i> , 2017 , 125, 817-830 | 3.9 | 34 |
| 61 | Cell free DNA analysis by SiRe next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1383-S1390 | 2.6 | 31 |
| 60 | mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3836-3843 | 2.6 | 29 |
| 59 | Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017 , 8, 23020-23032 | 3.3 | 26 |
| 58 | Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. <i>Journal of Clinical Pathology</i> , 2019 , 72, 38-45 | 3.9 | 25 |
| 57 | Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019 , 127, 285-296 | 3.9 | 24 |
| 56 | Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021 , 129, 460-4 | 46 7.9 | 22 |
| 55 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 810-820 | 8.9 | 19 |
| 54 | Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma. <i>Acta Histochemica</i> , 2015 , 117, 705-11 | 2 | 17 |
| 53 | Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919 | 6 | 17 |
| 52 | T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. <i>Translational Lung Cancer Research</i> , 2019 , 8, 584-592 | 4.4 | 15 |
| 51 | Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276 | 1.5 | 14 |
| 50 | Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. <i>Journal of Clinical Pathology</i> , 2017 , 70, 803-806 | 3.9 | 13 |

(2020-2018)

| 49 | , and mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. <i>Oncotarget</i> , 2018 , 9, 26279-26290 | 3.3 | 13 | |
|----|---|------|----|--|
| 48 | Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103525 | 7 | 12 | |
| 47 | EGFR mutation detection by microfluidic technology: a validation study. <i>Journal of Clinical Pathology</i> , 2013 , 66, 982-4 | 3.9 | 11 | |
| 46 | BRAF: A Two-Faced Janus. <i>Cells</i> , 2020 , 9, | 7.9 | 10 | |
| 45 | Microsatellite instability evaluation by automated microfluidic electrophoresis: an update. <i>Journal of Clinical Pathology</i> , 2017 , 70, 90-91 | 3.9 | 9 | |
| 44 | exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review <i>Translational Cancer Research</i> , 2019 , 8, S64-S69 | 0.3 | 9 | |
| 43 | RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83 | 7.5 | 8 | |
| 42 | Predictive molecular pathology in the time of COVID-19. <i>Journal of Clinical Pathology</i> , 2021 , 74, 234-237 | 73.9 | 8 | |
| 41 | Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , | 5.4 | 7 | |
| 40 | 2019, 11, 1758835919846421 Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 560 | 5.3 | 7 | |
| 39 | Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020 , 9, | 7.9 | 7 | |
| 38 | Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 161, 103311 | 7 | 7 | |
| 37 | Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2021 , 8, 633923 | 4.9 | 7 | |
| 36 | Next generation sequencing in cytology. <i>Cytopathology</i> , 2021 , 32, 588-595 | 1.3 | 6 | |
| 35 | RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021 , 13, | 6.6 | 6 | |
| 34 | A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic <i>Mediastinum</i> , 2021 , 5, 27 | 0.5 | 6 | |
| 33 | BRAF Mutations in Lung Cancer. <i>Acta Cytologica</i> , 2019 , 63, 247-250 | 3 | 5 | |
| 32 | Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe Panel. <i>Frontiers in Oncology</i> , 2020 , 10, 236 | 5.3 | 5 | |

| 31 | Liquid biopsy for mutations testing in non-small cell lung cancer: a retrospective study. <i>Journal of Clinical Pathology</i> , 2020 , | 3.9 | 5 |
|----|--|-----|---|
| 30 | TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2021 , | 3.9 | 4 |
| 29 | Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. <i>Histology and Histopathology</i> , 2020 , 35, 741-749 | 1.4 | 4 |
| 28 | Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. <i>Cells</i> , 2021 , 10, | 7.9 | 4 |
| 27 | Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 87-96 | 5.5 | 3 |
| 26 | Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021 , 2, 241-254 | 0.4 | 3 |
| 25 | Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 15, 231-242 | 6 | 3 |
| 24 | Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. <i>Journal of Clinical Pathology</i> , 2018 , 71, 1123-1126 | 3.9 | 3 |
| 23 | Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment. <i>Diagnostic Cytopathology</i> , 2019 , 47, 749-757 | 1.4 | 2 |
| 22 | Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. <i>Diagnostic Cytopathology</i> , 2020 , 48, 759-764 | 1.4 | 2 |
| 21 | Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2021 , | 3.9 | 2 |
| 20 | Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome <i>Journal of Clinical Oncology</i> , 2017 , 35, 644-644 | 2.2 | 1 |
| 19 | Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019 , 2, 130-136 | 0.6 | 1 |
| 18 | Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103300 | 7 | 1 |
| 17 | Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective. <i>Journal of Molecular Pathology</i> , 2021 , 2, 233-240 | 0.4 | 1 |
| 16 | Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103394 | 7 | 1 |
| 15 | The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 757-766 | 3.8 | 1 |
| 14 | Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103536 | 7 | O |

LIST OF PUBLICATIONS

| 13 | Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing <i>Journal of Clinical Oncology</i> , 2017 , 35, e1504 | 2.2 1-e15(| o 041 |
|----|---|---------------|----------|
| 12 | Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. <i>Journal of Molecular Pathology</i> , 2020 , 1, 36-42 | 0.4 | O |
| 11 | Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. <i>Annals of Translational Medicine</i> , 2021 , 9, 1027 | 3.2 | 0 |
| 10 | Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021 , 22, 833-847 | 2.6 | O |
| 9 | Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019 , 18, 491-492 | 2.1 | |
| 8 | Pathology in non-small cell lung cancer: evolving scenario. <i>Precision Cancer Medicine</i> , 2019 , 2, 17-17 | 1 | |
| 7 | Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours. <i>Journal of Clinical Pathology</i> , 2020 , 73, 602-604 | 3.9 | |
| 6 | Molecular Diagnostics: Innovative Technologies for Clinical and Translational Research. <i>UNIPA Springer Series</i> , 2021 , 137-151 | 0.1 | |
| 5 | Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers <i>Journal of Clinical Oncology</i> , 2018 , 36, e15517-e | 2.2 15517 | |
| 4 | DNA-Based Sequencing Assays 2019 , 83-97 | | |
| 3 | RNA-Based Assays 2019 , 99-119 | | |
| 2 | Predictive molecular pathology in metastatic thyroid cancer: the role of fusions Expert Review of Endocrinology and Metabolism, 2022, 1-12 | 4.1 | |
| 1 | Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. Journal of Molecular Pathology, 2021 , 2, 319-324 | 0.4 | |